MX2010004288A - Productos quimioterapeuticos cristalinos. - Google Patents

Productos quimioterapeuticos cristalinos.

Info

Publication number
MX2010004288A
MX2010004288A MX2010004288A MX2010004288A MX2010004288A MX 2010004288 A MX2010004288 A MX 2010004288A MX 2010004288 A MX2010004288 A MX 2010004288A MX 2010004288 A MX2010004288 A MX 2010004288A MX 2010004288 A MX2010004288 A MX 2010004288A
Authority
MX
Mexico
Prior art keywords
chemotherapeutic
crystalline
crystalline chemotherapeutic
methylpheny
indazol
Prior art date
Application number
MX2010004288A
Other languages
English (en)
Inventor
Thomas B Borchardt
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40174825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010004288A publication Critical patent/MX2010004288A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describe forma cristalina 1 de etanolato de N-[4-(3-amino-1H-indazol-4-iI)fenil]-N'-(2-fluoro-5-.metilfenil) urea 1/4, formas de elaborarla, formulaciones que la comprenden y elaboradas con la misma y m?todos que la utilizan para el tratamiento de pacientes enfermos.
MX2010004288A 2007-10-19 2008-10-16 Productos quimioterapeuticos cristalinos. MX2010004288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98131007P 2007-10-19 2007-10-19
PCT/US2008/080060 WO2009052225A1 (en) 2007-10-19 2008-10-16 Crystalline chemotherapeutic

Publications (1)

Publication Number Publication Date
MX2010004288A true MX2010004288A (es) 2010-04-30

Family

ID=40174825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004288A MX2010004288A (es) 2007-10-19 2008-10-16 Productos quimioterapeuticos cristalinos.

Country Status (25)

Country Link
US (1) US7994208B2 (es)
EP (1) EP2195300B1 (es)
JP (2) JP5878689B2 (es)
KR (1) KR20100085986A (es)
CN (1) CN101827821B (es)
AR (1) AR068918A1 (es)
AU (1) AU2008312528A1 (es)
BR (1) BRPI0818067A2 (es)
CA (1) CA2699302C (es)
CL (1) CL2008003091A1 (es)
CO (1) CO6280482A2 (es)
CR (1) CR11387A (es)
DO (1) DOP2010000113A (es)
EC (1) ECSP10010182A (es)
ES (1) ES2547878T3 (es)
GT (1) GT201000093A (es)
MX (1) MX2010004288A (es)
PA (1) PA8800301A1 (es)
PE (1) PE20091075A1 (es)
RU (1) RU2010119927A (es)
TW (1) TW200932728A (es)
UA (1) UA99747C2 (es)
UY (1) UY31408A1 (es)
WO (1) WO2009052225A1 (es)
ZA (1) ZA201002180B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US20140212355A1 (en) * 2013-01-28 2014-07-31 Abbott Cardiovascular Systems Inc. Trans-arterial drug delivery
JP7346916B2 (ja) * 2019-06-04 2023-09-20 京セラドキュメントソリューションズ株式会社 緩衝構造体およびそれを備えた包装材

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2346538T3 (es) * 2003-05-22 2010-10-18 Abbott Laboratories Inhibidores de quinasa de tipo indazol, benzisoxazol y benzisotiazol.
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) * 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007050574A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
CN101827821B (zh) 2012-09-05
EP2195300A1 (en) 2010-06-16
US7994208B2 (en) 2011-08-09
JP2015042650A (ja) 2015-03-05
UY31408A1 (es) 2009-05-29
TW200932728A (en) 2009-08-01
ES2547878T3 (es) 2015-10-09
ECSP10010182A (es) 2010-06-29
WO2009052225A1 (en) 2009-04-23
AR068918A1 (es) 2009-12-16
PA8800301A1 (es) 2009-08-26
CR11387A (es) 2010-08-18
DOP2010000113A (es) 2010-07-31
CA2699302A1 (en) 2009-04-23
CO6280482A2 (es) 2011-05-20
US20090105326A1 (en) 2009-04-23
CN101827821A (zh) 2010-09-08
EP2195300B1 (en) 2015-06-24
CA2699302C (en) 2016-06-21
GT201000093A (es) 2012-03-12
PE20091075A1 (es) 2009-08-27
KR20100085986A (ko) 2010-07-29
ZA201002180B (en) 2011-10-26
BRPI0818067A2 (pt) 2015-03-31
AU2008312528A1 (en) 2009-04-23
JP5878689B2 (ja) 2016-03-08
RU2010119927A (ru) 2011-11-27
UA99747C2 (en) 2012-09-25
JP2011500704A (ja) 2011-01-06
CL2008003091A1 (es) 2009-09-04

Similar Documents

Publication Publication Date Title
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
CL2011000716A1 (es) Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
RS51485B (en) USE OF AGOMELATIN FOR OBTAINING MEDICINES INTENDED FOR TREATMENT OF GENERALIZED ANXIETY DISORDER
WO2014081712A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
MX2010004290A (es) Productos quimioterapeuticos cristalinos.
MX2010004287A (es) Productos quimioterapeuticos cristalinos.
MX2010004288A (es) Productos quimioterapeuticos cristalinos.
MX2010003772A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il-1h-benzimidazol -4-carboxamida.
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
NZ525236A (en) Modafinil (C5H15NOS), 2- (benzhydryl-sulfinyl) acetamide, aka 2- [(diphenylmethyl) sulfinyl] acetamide in compositions of suspended particles, methods of preparation and uses thereof
WO2014081709A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
MX2010004286A (es) Productos quimioterapeuticos cristalinos derivados de indazol.
MX2010004289A (es) Productos quimioterapeuticos cristalinos.
MX2010003771A (es) Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.
MY148515A (en) Novel therapeutic use for treating of leukaemia
ATE435868T1 (de) Homogemcitabine
TH104744A (th) สารทางเคมีบำบัดที่เป็นผลึก
MX354403B (es) Uso del ambroxol [2-amino-3,5-dibromo-n-(trans-4-hidroxiciclohexil ) benzilamina] como agente antimicrobiano basado en sus propiedades; bactericida, fungicida y anti-biofilm.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights